Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CCNYL3, or putative cyclin-Y-like protein 3, is a predicted human protein encoded by the CCNYL3 gene, based on homology to cyclin Y family members. UniProt describes the gene and its product as “putative,” with no functional annotation, no reported biological functions, and no established links to cell signaling, transcription, or disease[5]. Unlike cyclin Y (CCNY), which is well-studied and involved in cell cycle regulation, signal transduction, and cancer, CCNYL3 is uncharacterized and lacking experimental validation, with no disease associations or evidence of clinical significance in the literature. If you need information about CCNY (cyclin Y) instead—which is an established regulator of cell cycle and signaling—please request it specifically, as CCNY is substantially annotated and experimentally characterized, while CCNYL3 is not[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Putative cyclin-Y-like protein 3 (CCNYL3).